AbbVie Inc. (ABBV): Shareholders' Equity
-$3.27B
As of 2025-12-31
-$5.93B
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$3.27B | n/m | 2026-02-20, Balance as of period end |
| 2024-12-31 | $3.33B | -67.9% | 2026-02-20, Balance as of period end |
| 2023-12-31 | $10.36B | -40.0% | 2025-02-14, Balance as of period end |
| 2022-12-31 | $17.25B | +12.0% | 2024-02-20, Balance as of period end |
| 2021-12-31 | $15.41B | +17.8% | 2023-02-17, Balance as of period end |
| 2020-12-31 | $13.08B | n/m | 2022-02-18, Balance as of period end |
| 2019-12-31 | -$8.17B | n/m | 2021-02-19, Balance as of period end |
| 2018-12-31 | -$8.45B | n/m | 2020-02-21, Balance as of period end |
| 2017-12-31 | $5.10B | +9.9% | 2020-02-21, Balance as of period end |
| 2016-12-31 | $4.64B | +17.5% | 2019-02-27, Balance as of period end |
| 2015-12-31 | $3.94B | +126.5% | 2018-02-16, Balance as of period end |
| 2014-12-31 | $1.74B | -61.2% | 2017-02-17, Balance as of period end |
| 2013-12-31 | $4.49B | n/m | 2016-02-19, Balance as of period end |
| 2012-12-31 | -$350.00M | n/a | 2014-02-21, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| AbbVie Inc. (ABBV) | 2025-12-31 | -$3.27B | n/m |
| Pfizer Inc (PFE) | 2025-12-31 | $86.78B | -1.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $52.66B | +13.6% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $26.54B | +85.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $18.47B | +13.1% |
| Abbott Laboratories (ABT) | 2025-12-31 | $52.13B | +9.4% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $81.54B | +14.1% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $7.91B | +47.1% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $31.26B | +6.5% |
Compare ABBV, PFE, MRK, LLY side by side · Screen every company in Pharmaceutical Preparations ↗